+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Chronic Myelogenous Leukemia Therapeutics Market - Global Forecast 2026-2032- Product Image
Chronic Myelogenous Leukemia Therapeutics Market - Global Forecast 2026-2032- Product Image
New

Chronic Myelogenous Leukemia Therapeutics Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 186 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 6010863
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The chronic myelogenous leukemia therapeutics market is rapidly evolving as advancements in molecular targeting, clinical pathways, and delivery models reshape the landscape. Senior decision-makers need granular, actionable intelligence to navigate emerging challenges in regulatory, clinical, and commercial domains.

Market Snapshot: Chronic Myelogenous Leukemia Therapeutics Market

The Chronic Myelogenous Leukemia (CML) Therapeutics Market expanded from USD 8.90 billion in 2025 to USD 9.59 billion in 2026 and is forecasted to grow at a CAGR of 8.02%, anticipated to reach USD 15.29 billion by 2032. This growth is driven by stakeholder focus on durable treatment responses, patient-centric care models, and the rapid adoption of targeted therapies across global health systems.

Scope & Segmentation

This report delivers in-depth coverage of all core dynamics affecting the CML therapeutics marketplace. Key segments and drivers analyzed include:

  • Therapy Types: Tyrosine kinase inhibitors (first-, second-, third-generation), chemotherapy agents, monoclonal antibodies, and combination regimens.
  • Treatment Lines: Differentiation by first-line, second-line, and later therapies, each with unique clinical positioning and resistance considerations.
  • Mechanisms of Action: Molecular targeting, cytotoxic chemotherapy, and combinatorial strategies to address resistance and deepen response.
  • Administration Routes: Oral, intravenous, and subcutaneous regimens, reflecting the shift from inpatient to outpatient and home-based care environments.
  • End-User and Channel Dynamics: Hospitals, clinics, specialty centers, home care, hospital pharmacies, retail, and online fulfillment.
  • Dosage Forms & Patient Segments: Capsules, tablets, injections; focus on adult, geriatric, and pediatric populations for tailored care and adherence initiatives.
  • Regions Covered: Americas, Europe, Middle East & Africa, and Asia-Pacific, each with specific regulatory, reimbursement, and delivery frameworks influencing adoption patterns.
  • Technology Solutions: Integration of precision diagnostics, real-world data, digital adherence monitoring, and specialty pharmacy partnerships to support clinical and operational needs.

Key Takeaways

  • Transition from broad cytotoxic chemotherapy toward targeted therapies is redefining stakeholder expectations regarding efficacy, safety, and quality of life.
  • Precision diagnostics and advanced monitoring support earlier detection of resistance, optimizing therapy sequencing and individualized patient management strategies.
  • Oral regimens facilitate decentralized care but elevate the priority of adherence programs and patient assistance, underscoring operational complexity in real-world delivery.
  • Regulatory bodies and payers are increasingly emphasizing robust comparative effectiveness and long-term data, driving extended real-world evidence generation and influencing formulary negotiations.
  • Regional variations in regulatory and reimbursement practices necessitate localized approaches to supply chain, pricing, and commercial distribution for sustained market access.
  • Strategic partnerships—spanning specialty pharmacies, diagnostics firms, and contract manufacturing organizations—are pivotal for supply resilience and competitive positioning.

Tariff Impact: 2025 United States Adjustments

  • Recent tariff adjustments in the United States have prompted manufacturers to reassess sourcing, invest in supply chain localization, and adopt dual-sourcing strategies.
  • Active pharmaceutical ingredient sourcing and cost variability from tariffs are addressed by contractual hedges and nearshoring of key manufacturing processes.
  • Payer and procurement scrutiny on cost stability and predictable supply has become integral to hospital and formulary decision-making.
  • Stakeholders advancing CML therapeutics prioritize supply chain transparency and flexible production capacity to avoid disruptions in access, particularly for oral and parenteral therapies.

Methodology & Data Sources

This report employs a transparent, multi-source research methodology, synthesizing targeted literature reviews, clinical trial analysis, and regulatory guideline evaluation. Direct interviews with clinicians, payers, and supply chain experts provide operational insights. Validation is achieved via the review of regulatory filings and specialty pharmacy reports to ensure findings are both actionable and regionally relevant.

Why This Report Matters

  • Delivers strategic clarity for R&D, market access, and supply chain leaders confronting evolving payer, regulatory, and clinical demands in the CML space.
  • Identifies segmentation nuances, regional variations, and delivery bottlenecks that matter for operational planning and commercial success.
  • Supports informed investment and partnership decisions by highlighting practical implications of emerging trends and policy changes.

Conclusion

Integrating clinical evidence, resilient supply strategies, and patient-centered delivery is fundamental to maximizing therapeutic impact in CML. Adaptive planning and operational agility will determine long-term stakeholder success in a transforming market.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Chronic Myelogenous Leukemia Therapeutics Market, by Therapy Type
8.1. Chemotherapy
8.1.1. Busulfan
8.1.2. Hydroxyurea
8.1.3. Interferon Alfa
8.2. Combination Agents
8.2.1. Tyrosine Kinase Inhibitor With Chemotherapy
8.2.2. Tyrosine Kinase Inhibitor With Monoclonal Antibody
8.3. Tyrosine Kinase Inhibitors
8.3.1. First Generation
8.3.2. Second Generation
8.3.2.1. Bosutinib
8.3.2.2. Dasatinib
8.3.2.3. Nilotinib
8.3.3. Third Generation
9. Chronic Myelogenous Leukemia Therapeutics Market, by Treatment Line
9.1. First Line
9.2. Second Line
9.3. Third Line And Beyond
10. Chronic Myelogenous Leukemia Therapeutics Market, by Mechanism Of Action
10.1. Chemotherapy
10.2. Combination Agents
10.3. Tyrosine Kinase Inhibition
11. Chronic Myelogenous Leukemia Therapeutics Market, by Route Of Administration
11.1. Oral
11.2. Parenteral
11.2.1. Intravenous
11.2.2. Subcutaneous
12. Chronic Myelogenous Leukemia Therapeutics Market, by Dosage Form
12.1. Capsule
12.2. Injection
12.3. Powder For Injection
12.4. Tablet
13. Chronic Myelogenous Leukemia Therapeutics Market, by Patient Age Group
13.1. Adult Patients
13.2. Geriatric Patients
13.3. Pediatric Patients
14. Chronic Myelogenous Leukemia Therapeutics Market, by End User
14.1. Clinics
14.2. Home Care Settings
14.3. Hospitals
14.4. Specialty Centers
15. Chronic Myelogenous Leukemia Therapeutics Market, by Distribution Channel
15.1. Hospital Pharmacies
15.2. Online Pharmacies
15.3. Retail Pharmacies
16. Chronic Myelogenous Leukemia Therapeutics Market, by Region
16.1. Americas
16.1.1. North America
16.1.2. Latin America
16.2. Europe, Middle East & Africa
16.2.1. Europe
16.2.2. Middle East
16.2.3. Africa
16.3. Asia-Pacific
17. Chronic Myelogenous Leukemia Therapeutics Market, by Group
17.1. ASEAN
17.2. GCC
17.3. European Union
17.4. BRICS
17.5. G7
17.6. NATO
18. Chronic Myelogenous Leukemia Therapeutics Market, by Country
18.1. United States
18.2. Canada
18.3. Mexico
18.4. Brazil
18.5. United Kingdom
18.6. Germany
18.7. France
18.8. Russia
18.9. Italy
18.10. Spain
18.11. China
18.12. India
18.13. Japan
18.14. Australia
18.15. South Korea
19. United States Chronic Myelogenous Leukemia Therapeutics Market
20. China Chronic Myelogenous Leukemia Therapeutics Market
21. Competitive Landscape
21.1. Market Concentration Analysis, 2025
21.1.1. Concentration Ratio (CR)
21.1.2. Herfindahl Hirschman Index (HHI)
21.2. Recent Developments & Impact Analysis, 2025
21.3. Product Portfolio Analysis, 2025
21.4. Benchmarking Analysis, 2025
21.5. AbbVie Inc.
21.6. Agios Pharmaceuticals, Inc.
21.7. Amgen Inc.
21.8. Amneal Pharmaceuticals, Inc.
21.9. Ascentage Pharma Group International Co., Ltd.
21.10. Astellas Pharma Inc.
21.11. AstraZeneca PLC
21.12. Aurobindo Pharma Limited
21.13. Bayer AG
21.14. Bristol-Myers Squibb Company
21.15. Cipla Limited
21.16. Dr. Reddy’s Laboratories Ltd
21.17. F. Hoffmann-La Roche Ltd.
21.18. GlaxoSmithKline plc
21.19. Hansoh Pharmaceutical Group Co., Ltd.
21.20. Hikma Pharmaceuticals PLC
21.21. Ilyang Pharmaceutical Co., Ltd.
21.22. Innovent Biologics, Inc.
21.23. Johnson & Johnson Services, Inc.
21.24. Lupin Limited
21.25. Merck & Co., Inc.
21.26. Novartis AG
21.27. Otsuka Holdings Co., Ltd.
21.28. Pfizer Inc.
21.29. Rasna Therapeutics, Inc.
21.30. Sanofi S.A.
21.31. Sun Pharmaceutical Industries Limited
21.32. Takeda Pharmaceutical Company Limited
21.33. Teva Pharmaceutical Industries Ltd.
21.34. Viatris Inc.
List of Figures
FIGURE 1. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 13. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 15. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 16. CHINA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY BUSULFAN, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY BUSULFAN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY BUSULFAN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY HYDROXYUREA, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY HYDROXYUREA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY HYDROXYUREA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY INTERFERON ALFA, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY INTERFERON ALFA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY INTERFERON ALFA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COMBINATION AGENTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COMBINATION AGENTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COMBINATION AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COMBINATION AGENTS, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITOR WITH CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITOR WITH CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITOR WITH CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITOR WITH MONOCLONAL ANTIBODY, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITOR WITH MONOCLONAL ANTIBODY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITOR WITH MONOCLONAL ANTIBODY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY FIRST GENERATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY FIRST GENERATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY FIRST GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY BOSUTINIB, BY REGION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY BOSUTINIB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY BOSUTINIB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DASATINIB, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DASATINIB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DASATINIB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY NILOTINIB, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY NILOTINIB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY NILOTINIB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD GENERATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD GENERATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD LINE AND BEYOND, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD LINE AND BEYOND, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COMBINATION AGENTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COMBINATION AGENTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COMBINATION AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITION, BY REGION, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY INJECTION, BY REGION, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY INJECTION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY POWDER FOR INJECTION, BY REGION, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY POWDER FOR INJECTION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY POWDER FOR INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ADULT PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ADULT PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY GERIATRIC PATIENTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY GERIATRIC PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY GERIATRIC PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PEDIATRIC PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PEDIATRIC PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
TABLE 111. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 112. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 113. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 114. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 115. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 116. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 117. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SPECIALTY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 118. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SPECIALTY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 119. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 120. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 121. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 122. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 123. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 124. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 125. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 126. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 127. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 128. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 129. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 130. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 131. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 132. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 133. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COMBINATION AGENTS, 2018-2032 (USD MILLION)
TABLE 134. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 135. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, 2018-2032 (USD MILLION)
TABLE 136. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
TABLE 137. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 138. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 139. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 140. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 141. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 142. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 143. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 144. NORTH AMERICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 145. NORTH AMERICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 146. NORTH AMERICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 147. NORTH AMERICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COMBINATION AGENTS, 2018-2032 (USD MILLION)
TABLE 148. NORTH AMERICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 149. NORTH AMERICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, 2018-2032 (USD MILLION)
TABLE 150. NORTH AMERICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
TABLE 151. NORTH AMERICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 152. NORTH AMERICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 153. NORTH AMERICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 154. NORTH AMERICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 155. NORTH AMERICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 156. NORTH AMERICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 157. NORTH AMERICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 158. LATIN AMERICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 159. LATIN AMERICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 160. LATIN AMERICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 161. LATIN AMERICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COMBINATION AGENTS, 2018-2032 (USD MILLION)
TABLE 162. LATIN AMERICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 163. LATIN AMERICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, 2018-2032 (USD MILLION)
TABLE 164. LATIN AMERICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
TABLE 165. LATIN AMERICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 166. LATIN AMERICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 167. LATIN AMERICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 168. LATIN AMERICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 169. LATIN AMERICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 170. LATIN AMERICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 171. LATIN AMERICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COMBINATION AGENTS, 2018-2032 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, 2018-2032 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 183. EUROPE, MIDDLE EAST & AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 184. EUROPE, MIDDLE EAST & AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 185. EUROPE, MIDDLE EAST & AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 186. EUROPE CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 187. EUROPE CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 188. EUROPE CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 189. EUROPE CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COMBINATION AGENTS, 2018-2032 (USD MILLION)
TABLE 190. EUROPE CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 191. EUROPE CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, 2018-2032 (USD MILLION)
TABLE 192. EUROPE CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
TABLE 193. EUROPE CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 194. EUROPE CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 195. EUROPE CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 196. EUROPE CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 197. EUROPE CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 198. EUROPE CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 199. EUROPE CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 200. MIDDLE EAST CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 201. MIDDLE EAST CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 202. MIDDLE EAST CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 203. MIDDLE EAST CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COMBINATION AGENTS, 2018-2032 (USD MILLION)
TABLE 204. MIDDLE EAST CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 205. MIDDLE EAST CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, 2018-2032 (USD MILLION)
TABLE 206. MIDDLE EAST CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
TABLE 207. MIDDLE EAST CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 208. MIDDLE EAST CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 209. MIDDLE EAST CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 210. MIDDLE EAST CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 211. MIDDLE EAST CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 212. MIDDLE EAST CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 213. MIDDLE EAST CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 214. AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 215. AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 216. AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 217. AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COMBINATION AGENTS, 2018-2032 (USD MILLION)
TABLE 218. AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 219. AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, 2018-2032 (USD MILLION)
TABLE 220. AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
TABLE 221. AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 222. AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 223. AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 224. AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 225. AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 226. AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 227. AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 228. ASIA-PACIFIC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 229. ASIA-PACIFIC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 230. ASIA-PACIFIC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 231. ASIA-PACIFIC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COMBINATION AGENTS, 2018-2032 (USD MILLION)
TABLE 232. ASIA-PACIFIC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 233. ASIA-PACIFIC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, 2018-2032 (USD MILLION)
TABLE 234. ASIA-PACIFIC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
TABLE 235. ASIA-PACIFIC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 236. ASIA-PACIFIC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 237. ASIA-PACIFIC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 238. ASIA-PACIFIC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 239. ASIA-PACIFIC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 240. ASIA-PACIFIC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 241. ASIA-PACIFIC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 242. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 243. ASEAN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 244. ASEAN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 245. ASEAN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 246. ASEAN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COMBINATION AGENTS, 2018-2032 (USD MILLION)
TABLE 247. ASEAN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 248. ASEAN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, 2018-2032 (USD MILLION)
TABLE 249. ASEAN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
TABLE 250. ASEAN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 251. ASEAN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 252. ASEAN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 253. ASEAN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 254. ASEAN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 255. ASEAN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 256. ASEAN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 257. GCC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 258. GCC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 259. GCC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 260. GCC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COMBINATION AGENTS, 2018-2032 (USD MILLION)
TABLE 261. GCC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 262. GCC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, 2018-2032 (USD MILLION)
TABLE 263. GCC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
TABLE 264. GCC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE

Companies Mentioned

The key companies profiled in this Chronic Myelogenous Leukemia Therapeutics market report include:
  • AbbVie Inc.
  • Agios Pharmaceuticals, Inc.
  • Amgen Inc.
  • Amneal Pharmaceuticals, Inc.
  • Ascentage Pharma Group International Co., Ltd.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Aurobindo Pharma Limited
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Dr. Reddy’s Laboratories Ltd
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Hansoh Pharmaceutical Group Co., Ltd.
  • Hikma Pharmaceuticals PLC
  • Ilyang Pharmaceutical Co., Ltd.
  • Innovent Biologics, Inc.
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Merck & Co., Inc.
  • Novartis AG
  • Otsuka Holdings Co., Ltd.
  • Pfizer Inc.
  • Rasna Therapeutics, Inc.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Limited
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.

Table Information

Report AttributeDetails
No. of Pages186
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 9.59 Billion
Forecasted Market Value ( USD ) by 2032 $ 15.29 Billion
Compound Annual Growth Rate8.0%
Regions CoveredGlobal
No. of Companies Mentioned31

Related Topics

Related Reports

Treating Chronic Myeloid Leukemia by Phase Market - Global Forecast 2026-2032 - Product Image

Treating Chronic Myeloid Leukemia by Phase Market - Global Forecast 2026-2032

  • Report
  • 196 Pages
  • Global
From
Treatment for Accelerated-Phase CML Market - Global Forecast 2025-2030 - Product Image

Treatment for Accelerated-Phase CML Market - Global Forecast 2025-2030

  • Report
  • 184 Pages
  • Global
From
Myeloproliferative Disorder Treatment - Market Insights, Competitive Landscape, and Market Forecast - 2032 - Product Image

Myeloproliferative Disorder Treatment - Market Insights, Competitive Landscape, and Market Forecast - 2032

  • Report
  • 150 Pages
  • Global
From
Dasatinib Drugs Market Report 2025 - Product Image

Dasatinib Drugs Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Acute Myeloid Leukemia Market Report and Forecast 2025-2034 - Product Image

Acute Myeloid Leukemia Market Report and Forecast 2025-2034

  • Report
  • 400 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.